6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction

被引:68
作者
Diaz, Philippe [1 ]
Phatak, Sharangdhar S. [2 ]
Xu, Jijun [1 ]
Astruc-Diaz, Fanny [1 ]
Cavasotto, Claudio N. [2 ]
Naguib, Mohamed [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Unit 409, Dept Anesthesiol & Pain Med, Houston, TX 77030 USA
[2] Univ Texas Houston, Hlth Sci Ctr, Sch Hlth Informat Sci, Houston, TX 77030 USA
关键词
PROTEIN-COUPLED RECEPTOR; ACID AMIDE HYDROLASE; CB2; RECEPTOR; NEUROPATHIC PAIN; CRYSTAL-STRUCTURE; LIGAND DOCKING; IN-VITRO; PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; BENZIMIDAZOLE DERIVATIVES;
D O I
10.1021/jm801353p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Recently, we discovered and reported a series of N-alkyl isatin acylhydrazone derivatives that are potent CB2 agonists. Here, we describe a novel series of selective CB2 inverse agonists resulting from introduction of a methoxy moiety in position 6 of the isatin scaffold. These novel 6-methoxy-N-alkyl isatin acylhydrazone derivatives exhibited high CB2 functional activity and selectivity at human CB2. Compound 16 (MDA77) had high activity (EC50 = 5.82 nM) at CB2 and no activity at CB1. Compound 15 (MDA55) (K-i = 89.9 nM, EC50 = 88.2 nM at CB2) inhibited the effect of compound 1 (MDA7), a selective CB2 agonist, in an animal model of neuropathic pain. The molecular modeling study presented here represents a first study of CB2 based on the structure of beta(2)-adrenergic receptor. A ligand-based homology model of the CB2 binding site was developed, and on the basis of our results, we propose a general binding mode for this class of inverse agonists with CB2.
引用
收藏
页码:433 / 444
页数:12
相关论文
共 77 条
[1]   SIR97:: a new tool for crystal structure determination and refinement [J].
Altomare, A ;
Burla, MC ;
Camalli, M ;
Cascarano, GL ;
Giacovazzo, C ;
Guagliardi, A ;
Moliterni, AGG ;
Polidori, G ;
Spagna, R .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1999, 32 :115-119
[2]   The effects of cannabinoids on the brain [J].
Ameri, A .
PROGRESS IN NEUROBIOLOGY, 1999, 58 (04) :315-348
[3]   Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective Agonists [J].
Ashton, John C. ;
Wright, Jason L. ;
McPartland, John M. ;
Tyndall, Joel D. A. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (14) :1428-1443
[4]  
Ballesteros J. A., 1995, METH NEUROSCI, P366, DOI [DOI 10.1016/S1043-9471, DOI 10.1016/S1043-9471(05)80049-7]
[5]   CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms [J].
Beltramo, M ;
Bernardini, N ;
Bertorelli, R ;
Campanella, M ;
Nicolussi, E ;
Fredduzzi, S ;
Reggiani, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (06) :1530-1538
[6]   Cannabinoid CB2 receptors in human brain inflammation [J].
Benito, C. ;
Tolon, R. M. ;
Pazos, M. R. ;
Nunez, E. ;
Castillo, A. I. ;
Romero, J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) :277-285
[7]   A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis [J].
Benito, C ;
Kim, WK ;
Chavarría, I ;
Hillard, CJ ;
Mackie, K ;
Tolón, RM ;
Williams, K ;
Romero, J .
JOURNAL OF NEUROSCIENCE, 2005, 25 (10) :2530-2536
[8]  
Benito C, 2003, J NEUROSCI, V23, P11136
[9]   4-(2,4-Dinitrophenylsulfanyl)morpholine [J].
Brito, Ivan ;
Lopez-Rodriguez, Matias ;
Cardenas, Alejandro ;
Vargas, Danitza .
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 2006, 62 :O461-O463
[10]   Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor [J].
Buckley , NE ;
McCoy, KL ;
Mezey, É ;
Bonner, T ;
Zimmer, A ;
Felder, CC ;
Glass, M ;
Zimmer, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 396 (2-3) :141-149